Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBPNASDAQ:CGONNYSE:JNJNASDAQ:UPBNASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$18.99-6.0%$24.70$14.35▼$36.37$645.96M1159,297 shs214,175 shsCGONCG Oncology$27.54-3.5%$28.07$23.91▼$46.99$2.09B1.6632,985 shs577,070 shsJNJJohnson & Johnson$161.14-1.3%$157.70$140.68▼$169.99$388.32B0.477.09 million shs7.46 million shsUPBUpstream Bio$7.63-0.9%$8.89$6.65▼$29.46$409.28MN/A323,767 shs118,134 shsUPBUpstream Bio$7.63-0.9%$8.89$6.65▼$29.46$409.28MN/A323,767 shs118,134 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma-6.04%-2.62%-29.85%-28.69%+11.97%CGONCG Oncology-3.47%+0.22%-1.11%-2.69%-32.43%JNJJohnson & Johnson-1.40%-1.89%-0.74%+10.48%+3.82%UPBUpstream Bio-0.91%-15.60%-4.39%-60.67%+762,999,900.00%UPBUpstream Bio-0.91%-15.60%-4.39%-60.67%+762,999,900.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVBPArriVent BioPharma1.4751 of 5 stars3.62.00.00.02.10.00.0CGONCG Oncology1.8517 of 5 stars3.62.00.00.02.70.80.0JNJJohnson & Johnson4.5105 of 5 stars2.33.04.23.92.92.51.3UPBUpstream BioN/AN/AN/AN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 3.17Buy$39.00105.37% UpsideCGONCG Oncology 3.10Buy$63.88131.94% UpsideJNJJohnson & Johnson 2.56Moderate Buy$171.336.33% UpsideUPBUpstream Bio 3.00Buy$56.50640.50% UpsideUPBUpstream Bio 3.00Buy$56.50640.50% UpsideCurrent Analyst Ratings BreakdownLatest UPB, CGON, AVBP, JNJ, and UPB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2025CGONCG OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.003/20/2025AVBPArriVent BioPharmaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.003/19/2025AVBPArriVent BioPharmaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/10/2025AVBPArriVent BioPharmaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$45.003/10/2025JNJJohnson & JohnsonGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/7/2025AVBPArriVent BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$39.00 ➝ $39.003/7/2025CGONCG OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$55.00 ➝ $55.003/5/2025JNJJohnson & JohnsonBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$159.00 ➝ $171.002/19/2025JNJJohnson & JohnsonRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.002/3/2025JNJJohnson & JohnsonGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$162.00 ➝ $166.001/28/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$159.00 ➝ $166.00(Data available from 3/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A($4.79) per shareN/ACGONCG Oncology$684K3,061.53N/AN/A($1.94) per share-14.20JNJJohnson & Johnson$88.82B4.37$13.24 per share12.17$29.69 per share5.43UPBUpstream Bio$2.37M172.69N/AN/AN/A∞UPBUpstream Bio$2.37M172.69N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$69.33M-$2.57N/AN/AN/AN/A-43.89%-29.67%3/27/2025 (Estimated)CGONCG Oncology-$48.61MN/A0.00N/AN/A-10,642.98%-18.97%-15.36%N/AJNJJohnson & Johnson$14.07B$6.6524.2314.562.5618.20%34.24%13.63%4/15/2025 (Estimated)UPBUpstream BioN/AN/A0.00N/AN/AN/AN/AN/A6/11/2025 (Estimated)UPBUpstream BioN/AN/A0.00N/AN/AN/AN/AN/A6/11/2025 (Estimated)Latest UPB, CGON, AVBP, JNJ, and UPB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/15/2025N/AJNJJohnson & Johnson$2.59N/AN/AN/A$21.65 billionN/A3/27/2025N/AAVBPArriVent BioPharma-$0.78N/AN/AN/AN/AN/A3/3/2025Q4 2024AVBPArriVent BioPharma-$0.78-$0.60+$0.18-$0.61N/AN/A1/22/2025Q4 2024JNJJohnson & Johnson$1.99$2.04+$0.05$1.41$22.44 billion$22.52 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/ACGONCG OncologyN/AN/AN/AN/AN/AJNJJohnson & Johnson$4.963.08%+5.43%74.59%63 YearsUPBUpstream BioN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ALatest UPB, CGON, AVBP, JNJ, and UPB DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/2/2025JNJJohnson & Johnsonquarterly$1.243.43%2/18/20252/18/20253/4/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A19.2819.28CGONCG OncologyN/A35.3235.32JNJJohnson & Johnson0.431.110.86UPBUpstream BioN/AN/AN/AUPBUpstream BioN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%CGONCG Oncology26.56%JNJJohnson & Johnson69.55%UPBUpstream BioN/AUPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharmaN/ACGONCG OncologyN/AJNJJohnson & Johnson0.16%UPBUpstream BioN/AUPBUpstream BioN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4034.02 millionN/AN/ACGONCG Oncology6176.04 millionN/AOptionableJNJJohnson & Johnson152,7002.41 billion2.40 billionOptionableUPBUpstream Bio3853.64 millionN/AN/AUPBUpstream Bio3853.64 millionN/AN/AUPB, CGON, AVBP, JNJ, and UPB HeadlinesRecent News About These CompaniesUpstream Bio, Inc.: Promising Outlook with Strategic Positioning and Strong Trial ExecutionMarch 19, 2025 | tipranks.comUpstream Bio (NASDAQ:UPB) Stock Price Down 7.3% - Time to Sell?March 19, 2025 | marketbeat.comQ1 EPS Estimates for Upstream Bio Boosted by William BlairMarch 16, 2025 | americanbankingnews.comWilliam Blair Forecasts Increased Earnings for Upstream BioMarch 15, 2025 | marketbeat.comUpstream Bio’s Financial Results and Strategic ProgressMarch 13, 2025 | tipranks.comPromising Developments and Strong Financial Position Drive Buy Rating for Upstream Bio, Inc.March 12, 2025 | tipranks.comUpstream Bio, Inc. Completes Enrollment in Phase 2 Trial of Verekitug for Chronic Rhinosinusitis and Raises $293 Million in IPOMarch 12, 2025 | quiverquant.comUpstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 12, 2025 | globenewswire.comUPB Upstream Bio, Inc.March 8, 2025 | seekingalpha.comPiper Sandler Remains a Buy on Upstream Bio, Inc. (UPB)March 4, 2025 | markets.businessinsider.comUpstream Bio to Present at Upcoming March Investor ConferencesFebruary 25, 2025 | globenewswire.comUpstream Bio, Inc. (UPB)January 25, 2025 | ca.finance.yahoo.comGlobal Upstream Bioprocessing Equipment Market Set to Soar, Projected to Reach USD 26.08 Billion by 2032January 6, 2025 | fmiblog.comUpstream Bio appoints GCDecember 27, 2024 | complianceweek.comNewly Public Biotech Startup Hires Life Sciences Veteran as GCDecember 17, 2024 | law.comUpstream Bio Appoints Allison Ambrose as General CounselDecember 17, 2024 | markets.businessinsider.comUpstream Bio to join Russell 2000 indexDecember 16, 2024 | msn.comUpstream Bio: Treating Respiratory Disorders With TSLP Targeting DifferentiationDecember 16, 2024 | seekingalpha.comUpstream Bio, Inc. to Join Russell 2000® Index Effective December 23, 2024December 16, 2024 | quiverquant.comUpstream Bio Announces Addition to Russell 2000® IndexDecember 16, 2024 | globenewswire.comUpstream Bio: Attractive, But Let's Wait For More Data And Lock-Up ExpiryDecember 7, 2024 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesPrice Targets on NVIDIA Rise in Front of EarningsBy Sarah Horvath | February 24, 2025View Price Targets on NVIDIA Rise in Front of EarningsWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyArcher Aviation Stock Skids: Mistaking Progress for Bad News?By Chris Markoch | February 24, 2025View Archer Aviation Stock Skids: Mistaking Progress for Bad News?Resilient Investing: 3 Stocks Built to Weather Market VolatilityBy Jeffrey Neal Johnson | March 17, 2025View Resilient Investing: 3 Stocks Built to Weather Market VolatilityUPB, CGON, AVBP, JNJ, and UPB Company DescriptionsArriVent BioPharma NASDAQ:AVBP$18.99 -1.22 (-6.04%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$19.70 +0.71 (+3.74%) As of 07:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.CG Oncology NASDAQ:CGON$27.54 -0.99 (-3.47%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$28.02 +0.48 (+1.74%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Johnson & Johnson NYSE:JNJ$161.14 -2.15 (-1.32%) Closing price 03/25/2025 03:58 PM EasternExtended Trading$161.30 +0.16 (+0.10%) As of 08:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Upstream Bio NASDAQ:UPB$7.63 -0.07 (-0.91%) As of 03/25/2025 04:00 PM EasternUpstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.Upstream Bio NASDAQ:UPB$7.63 -0.07 (-0.91%) As of 03/25/2025 04:00 PM EasternUpstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Insiders Sell: This Is What It Means for the Market Airship AI: Why This AI Penny Stock Is Poised for a Big Breakout Oklo’s Stock Price Meltdown Is an Opportunity to Buy Top Dividend Stocks With Over 10 Years of Hikes—and Room to Grow Quantum Gamble? Is IonQ's Stock an Opportunity or a Mirage? Will CrowdStrike's FedRAMP Authorization Move CRWD Stock? Top 3 Insider Stock Buys in March—Are They Still Good in April? Taiwan Semiconductor Attracts Big Money on NVIDIA Chip Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
